RFK ally confirms she was fired by FDA: ‘I learned so much and leave with no regrets’
Dr. Tracy Beth Hoeg has been removed from her role as the FDA's acting drug center director. Her departure follows a series of leadership changes at the agency, including the resignation of FDA Commissioner Marty Makary. Hoeg, who had been involved in scrutinizing the safety of various therapies, expressed that she leaves with no regrets after her time at the FDA.
- ▪Dr. Tracy Beth Hoeg was fired from her position leading the FDA's drug program.
- ▪She was replaced by Dr. Mike Davis, who previously served as deputy director.
- ▪Hoeg's removal is part of a broader shake-up at the FDA, which has seen multiple leadership changes recently.
Fortune files mainly under business. We currently carry 643 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fortune |
| Canonical URL | https://fortune.com/2026/05/16/who-is-tracy-beth-hoeg-fired-by-fda-rfk-maha-ally/ |
| Publication time | Sat, 16 May 2026 14:22:32 +0000 |
| Retrieval time | 2026-05-16T14:55:18.809Z |
| Last seen | 2026-05-16T14:55:18.809Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | _HUAfv7InK6v |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
A Food and Drug Administration official involved in scrutinizing the safety of antidepressants, COVID-19 vaccines and other widely used therapies has been removed from her role leading the agency’s drug program.Recommended Video Dr. Tracy Beth Hoeg will be replaced as FDA’s acting drug center director by Dr. Mike Davis, who has been serving as deputy director, according to an email sent to agency staff Friday that was obtained by The Associated Press. Hoeg said in a social media post late Friday that she was “fired,” from the agency, adding: “I learned so much and leave with no regrets.” Hoeg’s departure is the latest in an ongoing shake-up at the powerful regulatory agency. FDA Commissioner Marty Makary resigned earlier in the week, and Dr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fortune.
Discussion
0 commentsMore from Fortune
